Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam and Hydroxyzine Premedication to Reduce Side Effects of Ketamine Sedation in Pediatric Dental Patients
IRCT201602291882N8Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of midazolam, hydroxyzine and ketamine in anxiety disorder (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Reduction of ketamine sedation side effects. Started Oct 2014; status: completed.
02
Drugs
midazolamhydroxyzineketamine
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on IRCT201602291882N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201602291882N8.